High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1996 • 2,073 citations

Model Predicting Survival in Stage I Melanoma Based on Tumor Progression

1989 • 1,235 citations

A Multifactorial Analysis of Melanoma

1978 • 575 citations

Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases

1998 • 437 citations

A Multifactorial Analysis of Melanoma

1981 • 368 citations

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.

1998 • 366 citations

A Comparison of Prognostic Factors and Surgical Results in 1,786 Patients with Localized (Stage I) Melanoma Treated in Alabama, USA, and New South Wales, Australia

1982 • 354 citations

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

1997 • 302 citations

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.

1995 • 253 citations

Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.

1996 • 206 citations

Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.

1997 • 89 citations

Evaluation of efficacy of adjuvant rIFN-alfa-2a in melanoma patients with regional nodal metastases (abstract)

1995 • 57 citations

The large sample distribution of the weighted log rank statistic under general local alternatives.

1997 • 45 citations